SRX 251

Drug Profile

SRX 251

Alternative Names: API 251; SRX251

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Azevan Pharmaceuticals
  • Class Neuropsychotherapeutics
  • Mechanism of Action Vasopressin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Aggression
  • Discontinued Dysmenorrhoea

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Aggression in USA (PO)
  • 11 Jan 2010 SRX 251 is still in active development
  • 10 Dec 2009 Preclinical pharmacodynamics data presented at the 48th Annual Meeting of the American College of Neuropsychopharmacology (ACNP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top